GeoVax and NIH to develop vaccines against Ebola and Marburg viruses
Biotechnology firm GeoVax Labs has signed a research collaboration agreement with the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop its vaccines against Ebola and Marburg viruses.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Allergy & Immunology | Biotechnology | Ebola | Ebola Vaccine | Infectious Diseases | Marburg Virus | Pharmaceuticals | Vaccines